Parkinson Update: New Tricks and Old Drugs
New PD medications and treatments are being developed and novel uses for existing drugs are being discovered.
While there is no cure for Parkinson disease (PD) at this time, in the early stages of the disease, medications that mimic the action of dopamine and reduce the breakdown of dopamine are employed to control the motor symptoms patients experience. As researchers continue to learn more about the disease, new medications and treatments are being developed. Also, as described on the following pages, novel uses for existing drugs are being discovered.
New PD Treatment Strategy
♦ In a healthy brain, microglia cells serve as the first and primary immune response in the central nervous system.
♦ A flawed microglial inflammatory response could contribute to the neurodegeneration observed in PD.
♦ CU-CPT22 is a novel compound developed to suppress the misguided microglial inflammatory responses.
♦ The drug binds to microglia receptors to block inflammation.
♦
Receptor Responsible for PD Inflammation
♦ Alpha-synuclein (α-synuclein), although not completely understood, is a protein that likely helps maintain synaptic vesicles and regulate dopamine.
♦ In PD, α-synuclein accumulates, which may further trigger microglial inflammatory responses.
♦
♦ This reaction causes increases in the proinflammatory cytokines tumor necrosis factor-α (TNF-α) and interleukin-1β.
♦ Blocking the TLR1/2 receptor was found to reduce TNF-α secretion.
♦ A hypertension drug, candesartan cilexetil, inhibits TLR2 and reverses the cultured microglia proinflammatory phenotype exposed to α-synuclein.
♦ Candesartan cilexetil may be a future PD treatment.
PD Drug Also Used for Macular Degeneration?
♦ Levodopa (L-dopa) is a mainstay for the treatment of PD.
♦ L-dopa can cross the protective blood-brain barrier and replace the dopamine lost in PD.
Internal server error